The possibility and prospects of using cytostatics in patients with COVID-19 on the example of cyclophosphamide


DOI: https://dx.doi.org/10.18565/pharmateca.2021.1.10-13

V.M. Tsvetov (1), I.S. Burashnikova (2), D.A. Sychev (3), I.V. Poddubnaya (4)

1) Federal Center for Cardiovascular Surgery, Chelyabinsk, Russia, https://orcid.org/0000-0003-4810-2295; 2) Kazan State Medical Academy – branch of the Russian Medical Academy of Continuous Professional Education, Kazan, Russia, https://orcid.org/0000-0002-8511-5696; 3) Russian Medical Academy of Continuous Professional Education, Moscow, Russia, http://orcid.org/0000-0002-4496-3680; 4) Russian Medical Academy of Continuous Professional Education, Moscow, Russia, http://orcid.org/0000-0002-0995-1801
Currently, there is no evidence-based data to recommend the use of cyclophosphamide for the treatment of patients with COVID-19. The use of this drug may interfere with the course of SARS-CoV-2 infection, including development of adverse side effects. Clinical trials are required to evaluate the efficacy and safety of cytostatics, including cyclophosphamide, in patients with COVID-19.
Keywords: COVID-19, cytostatics, cyclophosphamide

Бионика Медиа